BCRX has 3 important milestones remaining in 2020:
1) Preliminary Galdesivir Ph I data of wuflu patients in Brazil 2) Additional Ph I dose escalation results in both PNH treatment naive and PNH patients taking CS inhibitors 3) 12/3 PDUFA
Galdesivir has worked in animal studies against other RNA viruses including Ebola, Marburg, Yellow Fever and Zika
BCX9030 data in PNH (Paroxysmal Nocturnal Hemoglobinuria) is due Q3/2020. This indication is a competitive space (ALXN , APLS); but, relative success in PNH could be a gateway to larger complement indications such as C3 glomerulopathy.
BCRX raised 140M 5/20 to bring cash to 225M EOQ1/20.
Cash burn for 2020 is estimated to be 125-150M
Cash runway thru mid 2021.
Assuming Berotralstat approval, at least one more cap raise will be necessary to bring BCRX to break even.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.